<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BEVACIZUMAB</span><br/>(be-va-ci-zu'mab)<br/><span class="topboxtradename">Avastin<br/></span><b>Classifications:</b> <span class="classification">biological response modifier</span>; <span class="classification">monoclonal antibody</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Binds to vascular endothelial growth factor (VEGF) and prevents the interaction of VEGF to its receptors on the surface of
         endothelial cells. This blocks endothelial cell proliferation and new blood vessel formation in tumor cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Believed to cause reduction of microvascularization in the tumor inhibiting the progression of metastatic disease.</p>
<h1><a name="uses">Uses</a></h1>
<p>Metastatic colorectal cancer.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Metastatic renal cell cancer.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Pregnancy (category C), lactation; nephrotic syndrome; active bleeding; surgery within 28 d; dental work within 20 d. Safety
         and effectiveness in children are not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to bevacizumab; hypertension, history of arterial thromboembolic, cardiovascular, or cerebrovascular disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Metastatic Colorectal Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 5 mg/kg q14d until disease progression<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">
<b>Intravenous</b>
</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Withdraw the desired dose of 5 mg/kg and dilute in 100 mL of NS injection. Do not shake and do <small>NOT</small> mix or administer with dextrose solutions. Discard any unused portion.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span>
<small>DO NOT</small> administer IV push or bolus. Infuse first dose over 90 min; if well tolerated, infuse second dose over 60 min; if well tolerated,
                  infuse all subsequent doses over 30 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Dextrose</b>-containing solutions. <span class="incompattype"> Y-site:</span>
<b> Dextrose</b>-containing solutions. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store diluted solution at 2°8° C (36°46° F) for up to 8 h. Store vials at 2°8°
            C (36°46° F) and protect from light.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span>
<span class="speceff-common">Asthenia</span>
<i>,</i> pain, wound dehiscence. <span class="typehead">CNS:</span> Syncope, headache, dizziness, confusion, abnormal gait. <span class="typehead">CV:</span> DVT, <span class="speceff-common">hypertension</span>
<i>,</i> heart failure, intra-abdominal thrombosis, <span class="speceff-life">cerebrovascular events</span>. <span class="typehead">GI:</span> Abdominal pain, <span class="speceff-common">diarrhea</span>
<i>,</i> constipation, nausea, vomiting, anorexia, stomatitis, dyspepsia, weight loss, flatulence, dry mouth, colitis, <span class="speceff-life">gastrointestinal perforation</span>. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Leukopenia, neutropenia</span>
<i>,</i> thrombocytopenia, <span class="speceff-common">thromboembolism</span>
<i>.</i>
<span class="typehead">Metabolic:</span> Hypokalemia, hyperbilirubinemia. <span class="typehead"> Musculoskeletal:</span> Myalgia. <span class="typehead">Respiratory:</span>  Upper respiratory infection, epistaxis, dyspnea, <span class="speceff-life">hemoptysis</span>. <span class="typehead">Skin:</span> Exfoliative dermatitis, alopecia. <span class="typehead">Special Senses:</span> Taste disorder, increased tearing. <span class="typehead">Urogenital:</span>
<span class="speceff-common">Proteinuria</span>
<i>,</i> urinary frequency/urgency. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> None reported at this time. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Half-Life:</span> 20 d (1150 d). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of an infusion reaction (hypersensitivity); infusion should be interrupted in all patients with severe infusion
            reactions and appropriate therapy instituted.
         </li>
<li>Monitor BP at least every 23 wk; if hypertension develops, monitor more frequently, even after discontinuation of bevacizumab.</li>
<li>Withhold drug and promptly notify physician for S&amp;S of CHF, hemorrhage (e.g., epistaxis, hemoptysis, or GI bleeding), or unexplained
            abdominal pain.
         </li>
<li>Lab tests: Urinalysis for proteinuria and 24 h urine if protein 2+ or greater.</li>
<li>Monitor for dizziness, lightheadedness, or loss of balance. Take appropriate safety measures.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to the physician: bloody or black, tarry stool; changes in patterns of urination; swelling of
            legs or ankles; increased shortness of breath; severe abdominal pain; change in mental awareness, inability to talk or move
            one side of the body.
         </li>
<li>Women of childbearing age should use effective birth control while receiving bevacizumab.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>